<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112618">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01897766</url>
  </required_header>
  <id_info>
    <org_study_id>A6281314</org_study_id>
    <nct_id>NCT01897766</nct_id>
  </id_info>
  <brief_title>Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)</brief_title>
  <official_title>Genotropin (Somatropin) Long Term Special Investigation For Patients With A Small For Gestational Age (SGA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this surveillance is to collect Safety and Effectiveness information for
      Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes Genotropin should be registered
      consecutively until the number of subjects reaches target number in order to extract
      patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Change in growth rate SD score for calendar age</measure>
    <time_frame>6 years maximum</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in height SD score for calendar age</measure>
    <time_frame>6 years maximum</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final height</measure>
    <time_frame>6 years maximum</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Small for Gestational Age (SGA)</condition>
  <arm_group>
    <arm_group_label>Somatropin</arm_group_label>
    <description>Patients administered Somatropin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>0.23 mg to 0.48 mg/kg/week</description>
    <arm_group_label>Somatropin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  A patients who is diagnosed for SGA. (SGA is defined as birth weight and/or length at
             least 2 standard deviations (SDs) below the mean for gestational age (&lt;or=-2 SD)).

          -  A patient who is SGA and older than 3 years.

          -  A patient who has persistent short stature (i.e., remaining at least 2.5 SD below the
             mean for chronologic age).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient who was administered Somatropin (Genotropin).

        Exclusion Criteria:

          -  N/A.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281314&amp;StudyName=Special%20Investigation%20Of%20Genotropin%20Long%20Follow-Up%20For%20Patients%20With%20A%20Small%20For%20Gestational%20Age%20%28SGA%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotropin</keyword>
  <keyword>Somatropin</keyword>
  <keyword>Long Term Follow-Up</keyword>
  <keyword>Special Investigation</keyword>
  <keyword>Small for Gestational Age</keyword>
  <keyword>SGA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
